JZP-110: Completed Ph III 14-002 enrollment

Jazz completed enrollment of 240 patients in the double-blind, placebo-controlled, North American Phase III Study 14-002 evaluating 75, 150 and 300 mg oral JZP-110 once daily for 12 weeks. Patients ma...